In a society where being thin is often equated with beauty and success, South Korea is grappling with a disturbing trend: the rampant misuse of diet drugs. But here's where it gets controversial—despite having one of the lowest obesity rates in the OECD, the country is witnessing a surge in demand for weight-loss medications, driven by skyrocketing body-image pressures and easy access to these drugs. This phenomenon raises critical questions about the intersection of health, aesthetics, and societal expectations.
The Skinny on South Korea’s Diet Drug Boom
South Korea, already one of the leanest nations in the Organisation for Economic Co-operation and Development (OECD), is experiencing an unprecedented wave of interest in weight-loss medications. This trend is fueled by a toxic combination of social media-driven beauty standards and the availability of drugs that promise quick results. Health authorities are sounding the alarm, warning that this growing demand is leading to misuse, with potentially severe health consequences.
Adding to the complexity, a new generation of oral GLP-1 medications is set to hit the South Korean market as early as 2026. Eli Lilly’s orforglipron and Novo Nordisk’s oral semaglutide are among the drugs awaiting approval, promising expanded treatment options for obesity and diabetes. Meanwhile, South Korea’s own Hanmi Pharmaceutical is gearing up to release efpeglenatide in the second half of 2026. And this is the part most people miss—while these drugs are designed to address serious health issues, their misuse for cosmetic purposes is becoming alarmingly common.
The Dark Side of Thinness
Obesity, a global health challenge, has prompted the World Health Organization (WHO) to issue its first guidelines recommending GLP-1 therapies as a treatment for obesity as a chronic, relapsing disease. Yet, in South Korea, where the obesity rate stands at just 5.7% under WHO standards, the focus on thinness has taken a dangerous turn. The country’s stricter BMI threshold of 25 or above for defining obesity reveals a different picture: 41.4% of men and 23% of women are classified as obese, with these numbers steadily rising.
Despite their medical purpose, anti-obesity drugs like Novo Nordisk’s Wegovy have become popular for aesthetic weight loss. Introduced in Korea in October 2024, Wegovy has already shown signs of widespread misuse. Shockingly, the Health Insurance Review & Assessment Service reported that the drug was illegally prescribed to 69 children under 12 and 194 pregnant women—groups explicitly barred from using it. Even more concerning, large numbers of prescriptions were written by specialists unrelated to obesity treatment, such as psychiatrists, urologists, and dentists.
Social Media: The Silent Culprit
Experts argue that South Korea’s obsession with thinness has been amplified by social media. In July, the Korea Health Promotion Institute issued a public advisory against “distorted body ideals” spreading online, particularly the alarming trend of the “bony arm,” where arms so thin that bone outlines are visible are glorified. This normalization of extreme thinness has contributed to a 39% increase in eating-disorder patients between 2020 and 2023.
A study by professors at Changwon National University and Soongsil University found that young women exposed to pro-anorexia content often describe a dangerous progression: from longing for thinness to achieving and maintaining it, frequently reinforced by online communities. International research, including Facebook’s internal studies reported by the Wall Street Journal in 2021, highlights how platforms like Instagram exacerbate body-image issues among teenage girls.
The Gender Paradox
Here’s a startling fact: while men are nearly twice as likely as women to be classified as obese under South Korea’s BMI 25 standard, women accounted for 71.5% of all prescriptions for Wegovy and Saxenda between 2020 and June 2025. This disparity raises questions about societal pressures on women to conform to unrealistic beauty standards. Is this a reflection of deeper gender inequalities, or simply a matter of personal choice?
The Road Ahead
As South Korea’s obesity rate continues to rise—reaching 34.4% in 2024 under the BMI 25 threshold—public understanding of obesity remains limited. A survey by the Korean Society for the Study of Obesity revealed that only 38% of non-medical respondents viewed obesity as a disease, compared to 90% of doctors. Many still believe it can be overcome through willpower alone.
Health authorities are urging caution, emphasizing that while increased access to treatment is justified for medically obese patients, casual or cosmetic use of GLP-1 drugs poses unnecessary risks. In October, the Ministry of Health and Welfare announced plans to designate Wegovy, Saxenda, and other anti-obesity drugs as medications at risk of misuse or abuse.
Food for Thought
As we navigate this complex issue, it’s worth asking: Are we prioritizing appearance over health? And at what cost? The misuse of diet drugs in South Korea is not just a health crisis—it’s a reflection of deeper societal values. What do you think? Is the pursuit of thinness worth the risks, or is it time to redefine beauty standards? Let’s start the conversation.
